Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Cancer

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

In Vivo Assessment of dbDNA GNE<sup>wt</sup>/bi-shRNA-GNE<sup>M743T</sup> Lipoplex for GNE Myopathy: Improved Potency and Safety.

The journal of gene medicine·2026

Same author

Preclinical assessment of GNE<sup>wt</sup>/bi-shRNA-GNE<sup>M743T</sup> lipoplex product development for GNE myopathy.

Future science OA·2026

Same author

Gemogenovatucel-T Advantage in Clonal Tumor Mutation Burden-High Ovarian Cancer.

JCO precision oncology·2026

Same author

Clinical characterization and therapeutic targeting of fusion genes in oncology.

Future oncology (London, England)·2025

Same author

Exome sequencing shows same pattern of clonal tumor mutational burden, intratumor heterogenicity and clonal neoantigen between autologous tumor and Vigil product.

Scientific reports·2025

Same author

Repair Assisted Damage Detection (RADD) as a predictive biomarker for immunotherapy response in ovarian cancer.

Gynecologic oncology·2024

Search research articles

Related Experiment Video

Updated: May 13, 2026

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

RNA interference and personalized cancer therapy.

Donald D Rao¹, Zhaohui Wang, Neil Senzer

¹Gradalis, Inc., 1700 Pacific Ave., Suite 1100, Dallas, Texas 75201, USA.

Discovery Medicine

|March 2, 2013

Summary

RNA interference (RNAi) offers a novel "one-two punch" cancer therapy. This approach targets vulnerable genes to reduce tumors and prime the immune system for attack, advancing personalized cancer treatment.

More Related Videos

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

Related Experiment Videos

Last Updated: May 13, 2026

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

Area of Science:

Oncology
Molecular Biology
Bioinformatics

Background:

Cancer remains a leading cause of death, with limited success in treating advanced stages.
Tumor biology is complex and unique to each patient, necessitating personalized treatment strategies.
Current treatments often fall short, highlighting the need for innovative therapeutic approaches.

Purpose of the Study:

To explore the potential of RNA interference (RNAi) technology in advanced cancer treatment.
To introduce a sequential "one-two punch" therapeutic strategy combining gene knockdown and immune activation.
To demonstrate how advanced bioinformatics and proteo-genomics can identify therapeutic targets in individual tumors.

Main Methods:

Utilizing advancements in proteo-genomics and bioinformatics to analyze complex tumor biology.
Employing RNA interference (RNAi) to target and knock down specific genes crucial for tumor maintenance.
Developing a sequential treatment approach involving multi-target gene knockdown followed by immune activation.

Main Results:

RNAi technology can effectively target vulnerable genes with minimal side effects.
The "one-two punch" approach aims to reduce tumor volume and prime the tumor microenvironment for immune attack.
This strategy has the potential to block intrinsic immunosuppressors and enhance anti-tumor immunity.

Conclusions:

RNAi-based sequential therapy represents a powerful new direction in personalized cancer treatment.
Targeting vulnerable "omic" rewiring nodes offers a precise strategy for combating advanced cancers.
This approach holds promise for improving outcomes in advanced cancer patients by combining tumor reduction with immune priming.